Your browser doesn't support javascript.
loading
Blocking preferential glucose uptake sensitizes liver tumor-initiating cells to glucose restriction and sorafenib treatment.
Zhang, Hui-Lu; Wang, Ming-Da; Zhou, Xu; Qin, Chen-Jie; Fu, Gong-Bo; Tang, Liang; Wu, Han; Huang, Shuai; Zhao, Ling-Hao; Zeng, Min; Liu, Jiao; Cao, Dan; Guo, Lin-Na; Wang, Hong-Yang; Yan, He-Xin; Liu, Jie.
Afiliação
  • Zhang HL; Department of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai 200040, China.
  • Wang MD; International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, The Second Military Medical University, Shanghai 200438, China.
  • Zhou X; International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, The Second Military Medical University, Shanghai 200438, China.
  • Qin CJ; International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, The Second Military Medical University, Shanghai 200438, China.
  • Fu GB; International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, The Second Military Medical University, Shanghai 200438, China.
  • Tang L; International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, The Second Military Medical University, Shanghai 200438, China; National Center for Liver Cancer Research, Shanghai 201805, China.
  • Wu H; International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, The Second Military Medical University, Shanghai 200438, China.
  • Huang S; International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, The Second Military Medical University, Shanghai 200438, China.
  • Zhao LH; International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, The Second Military Medical University, Shanghai 200438, China.
  • Zeng M; International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, The Second Military Medical University, Shanghai 200438, China.
  • Liu J; International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, The Second Military Medical University, Shanghai 200438, China.
  • Cao D; International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, The Second Military Medical University, Shanghai 200438, China.
  • Guo LN; International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, The Second Military Medical University, Shanghai 200438, China.
  • Wang HY; International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, The Second Military Medical University, Shanghai 200438, China; National Center for Liver Cancer Research, Shanghai 201805, China. Electronic address: hywangk@vip.sina.com.
  • Yan HX; International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, The Second Military Medical University, Shanghai 200438, China; National Center for Liver Cancer Research, Shanghai 201805, China. Electronic address: hexinyw@163.com.
  • Liu J; Department of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai 200040, China. Electronic address: jieliu@fudan.edu.cn.
Cancer Lett ; 388: 1-11, 2017 03 01.
Article em En | MEDLINE | ID: mdl-27894955
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos de Fenilureia / Células-Tronco Neoplásicas / Niacinamida / Carcinoma Hepatocelular / Neoplasias Hepáticas / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cancer Lett Ano de publicação: 2017 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos de Fenilureia / Células-Tronco Neoplásicas / Niacinamida / Carcinoma Hepatocelular / Neoplasias Hepáticas / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cancer Lett Ano de publicação: 2017 Tipo de documento: Article País de afiliação: China